Rapamycin is an effective inhibitor of human renal cancer metastasis Academic Article uri icon

Overview

MeSH Major

  • Antibiotics, Antineoplastic
  • Kidney Neoplasms
  • Lung Neoplasms
  • Sirolimus

abstract

  • Our findings support the idea that rapamycin may be of value for patients with RCC and that its antitumor efficacy is realized by cell cycle arrest and targeted reduction of VEGF-A and TGF-beta1. A regimen of rapamycin and cyclosporine, demonstrated to be effective in reducing acute rejection of renal allografts, may prevent RCC progression as well, and has the potential to prevent mortality due to RCC in patients with ESRD who have received renal allografts.

publication date

  • March 2003

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1046/j.1523-1755.2003.00805.x

PubMed ID

  • 12631072

Additional Document Info

start page

  • 917

end page

  • 26

volume

  • 63

number

  • 3